<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184583</url>
  </required_header>
  <id_info>
    <org_study_id>ANZHEN HOSPITOL-LY-02</org_study_id>
    <nct_id>NCT04184583</nct_id>
  </id_info>
  <brief_title>Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome</brief_title>
  <official_title>Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Registry Study on Drug Therapy and Clinical Outcomes in Patients With Acute Coronary Syndrome
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2019</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>main adverse cardiovascular and cerebrovascular events (MACCE)</measure>
    <time_frame>up to 5 years</time_frame>
    <description>MACCE will be defined as all-cause death, non-fatal stroke, non-fatal myocardial infarction (MI), and ischemic-driven revascularization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Adverse drug reaction will be defined as any adverse reactions in the patients.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Drug Therapy</condition>
  <condition>Acute Coronary Syndrome</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Part of DNA samples were preserved in the -80℃.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Acute Coronary Syndrome with blood concentration monitoring or genetic
        testing at the pharmacy department of Beijing Anzhen Hospital from January 1, 2018.Those
        who fill the inclusion criteria at screening will be invited for the registry study into
        different groups.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent has been signed.

          -  Patients diagnosed in our hospital with acute coronary syndrome.

          -  Age ≥18.

          -  Life expectancy ≥12 months.

        Exclusion Criteria:

          -  Severe lack of important information such as history of previous medication, history
             of previous disease, history of surgery.

          -  Pregnant and lactating women.

          -  Mental disorders, or inability to communicate effectively with researchers, or failure
             to comply with research protocols.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yi Zhang, PhD</last_name>
    <phone>86-010-64456609</phone>
    <email>phd-zhangyi@outlook.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yang Lin, PhD</last_name>
    <phone>86-010-64456609</phone>
    <email>linyang3623@outlook.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yang Lin, PhD</last_name>
      <phone>86-010-64456609</phone>
      <email>linyang3623@outlook.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiujing Shi, MD</last_name>
      <phone>86-010-64456609</phone>
      <email>xiujingshi@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 3, 2019</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Lin Yang</investigator_full_name>
    <investigator_title>Director of pharmacy department of Beijing Anzhen Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

